On Monday, Following U.S. Stocks were among the “Top Losers”: Hercules Offshore, (NASDAQ:HERO), Ocwen Financial (NYSE:OCN), Memorial Resource Development (NASDAQ:MRD), Enzo Biochem,(NYSE:ENZ)

Hercules Offshore, Inc. (NASDAQ:HERO), with shares declined -7.88%, closed at $0.373.

Ocwen Financial Corp (NYSE:OCN), with shares dropped -7.79%, settled at $8.64.

Memorial Resource Development Corp (NASDAQ:MRD), with shares dipped -7.58%, and closed at $16.21.

Enzo Biochem, Inc. (NYSE:ENZ), plummeted -7.55%, and closed at $3.06.

Latest NEWS regarding these Stocks are depicted underneath:

Hercules Offshore, Inc. (NASDAQ:HERO)

A research report sent to shareholders on Friday morning stated that Howard Weil cut shares of Hercules Offshore, Inc. (HERO), from an outperform rating to a sector perform rating. Stock institutional ownership is 52.00% while insider ownership comprises 3.40%.

Hercules Offshore, Inc., together with its auxiliaries, provides shallow-water drilling and marine services to the oil and natural gas exploration and production industry worldwide.

Ocwen Financial Corp. (NYSE:OCN)

Ocwen Financial Corp. (OCN), holds a Zacks Rank #2 (Strong Buy). The stocks’ earnings estimates for the current year have been revised significantly upward over the last 60 days.

Formerly on March 2, a leading financial services holding corporation, stated noteworthy updates about the Corporation.

As formerly revealed on February 5, 2015 in its Corporation Update to Stakeholders, Ocwen anticipates to report a loss for the fourth quarter and 2014 fiscal year.

In that Form 8-K filing, the Corporation revealed the following items related to its fourth quarter results.

• It recorded an additional $50 million expense related to its New York Department of Financial Services Settlement.
• The Corporation anticipates to raise expenses related to uncollectable receivables and other servicing expenses by about $64 million.
• The Corporation anticipates the expense for third party monitoring costs in the fourth quarter of 2014 to be about $13 million.

In addition to these formerly revealed items, the Corporation anticipates that its fourth quarter results will be influenced by the following non-recurring items:

• A $370 — $420 million non-cash charge to write-off goodwill.
• The creation of a $15 million reserve regarding its remediation plan to address issues around certain erroneously dated borrower correspondence.

Ocwen Financial Corporation, through its auxiliaries, is engaged in the servicing and origination of mortgage loans in the United States and internationally. Ocwen is headquartered in Atlanta, Georgia, with offices throughout the United States and support operations in India and the Philippines.

Memorial Resource Development Corp. (NASDAQ:MRD)

Memorial Resource Development Corp. (MRD) declared its operating and financial results for the fourth quarter and year ended December 31, 2014.

Financial highlights of Memorial Resource Development Corp. (MRD)‘s fourth quarter 2014 comprise:

• Raised average daily production 104% to 282 MMcfe/d for the fourth quarter 2014 contrast to 139 MMcfe/d for the fourth quarter 2013
• Represents a 21% sequential raise from 234 MMcfe/d in the third quarter 2014
• Raised Adjusted EBITDA(1) 119% to $96.6 million for the fourth quarter 2014 contrast to $44.2 million in the preceding year period

Financial highlights from full year 2014 comprise:

• Raised average daily production 77% to 227 MMcfe/d for 2014 contrast to 128 MMcfe/d in 2013
• Raised average daily production in the Terryville Field 89% to 195 MMcfe/d for 2014 as compared to 103 MMcfe/d in 2013
• Raised Adjusted EBITDA(1) 74% to $344.0 million in 2014 as compared to $197.9 million in 2013

Memorial Resource Development Corp., an independent natural gas and oil corporation, focuses on the attainment, exploitation, and development of natural gas, natural gas liquids, and oil properties in North Louisiana, in addition to the Rocky Mountains.

Enzo Biochem Inc. (NYSE:ENZ)

Enzo Biochem Inc. (ENZ), said, acting upon advice of counsel, that it disagrees with the March 16, 2015 split 2-to-1 decision of the Court of Appeals sitting in panel for the Federal Circuit that reverses-in-part and vacates-in-part the judgment in Enzo’s favor that Applera Corp., now Life Technologies, Inc. (NASDAQ:LIFE), infringed Enzo’s patents covering pioneering technologies regarding compounds used in DNA sequencing systems to read the genetic code, and remands the case to the District Court as to whether the accused product infringes.

Counter to the District Court’s construction of the ‘767 patent as allowing for directly-detectable labels on nucleotides and polynucleotides, and counter to the jury’s verdict that the patent describes such labelling, the Court of Appeals, held such labelling excluded by claim 1 of that patent.

Enzo notes also that the Court’s partial vacatur and reversal of the judgment does not end the case, but remands the case back to the District Court to find whether the accused product infringes.

Enzo will request rehearing of that decision, both by the original panel and by the full en banc Court. Enzo believes rehearing is warranted by the panel’s failure to give appropriate weight to fact findings, counting facts found by the jury, consistent with a broader construction of the patent, as required by the Supreme Court’s recent decision in Teva Pharmaceuticals.

Enzo Biochem, Inc., an integrated life sciences and biotechnology corporation, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.